Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy

Retina

Volumn 27, Issue 2, 2007, Pages 222-235

  Roldán Pallarés, Manuela ^a,c   Rollín, Raquel ^a   Martínez Montero, Juan Carlos ^b   Fernández Cruz, Arturo ^a   Bravo Llata, Carmen ^a   Fernández Durango, Raquel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c NONE   (Spain)

Author keywords

Epiretinal membranes; Immunoreactive endothelin 1; Proliferative diabetic retinopathy; Vitreous humor

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MITOGENESIS; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; ENDOTHELIN-1; EPIRETINAL MEMBRANE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VITREOUS BODY;

EID: 33846944666     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iae.0000231376.76601.40     Document Type: Article

References (52)

1. Deng D, Evans T, Mukherjee K, et al. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999;42:1228-1234.
2. Soriano FG, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly (ADP-ribose) polymerase activation. Nat Med 2001;7:108-113.
3. Ferrara N, Davis-Smith T. The biology of vascular endothelium growth factor. Endocr Rev 1997;18:4-23.
4. Bikfalvi A, Klein S, Pintucci G, et al. Biological role of fibroblast growth factor-2. Endocr Rev 1997;18:22-45.
5. Aiello LP, Avery RL, Arrig PG, et al. Vascular endothelial growth factor in ocular fluid of patients with retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
6. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994;145:574-584.
7. Matsuura A, Yamochi W, Hirata K, et al. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998;32:89-95.
8. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
9. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-732.
10. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of endothelin receptor. Nature 1990;348:732-735.
11. Polak K, Luksch A, Frank B, et al. Regulation of human retinal blood flow by endothelin-1. Exp Eye Res 2003;76:633-640.
12. Polak K, Petternel V, Luksch A, et al. Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci 2001;42:2949-2956.
13. Haefliger IO, Flammer J, Luscher TF. Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci 1992;33:2340-2343.
14. Morbidelli L, Orlando C, Maggi CA, et al. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 1995;38:686-695.
15. Goligorsky MS, Budzikowski AS, Tsukahara T, et al. Cooperation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol 1999;26:269-271.
16. Alberts GF, Peifley KA, Johns A, et al. Constitutive endothelin-1 overexpression promotes smooth muscle cells proliferation via an external autocrine loop. J Biol Chem 1994;269:10112-10118.
17. Bagnato A, Salani D, di Castro V, et al. Expression of endothelin-1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumour growth. Cancer Res 1999;59:720-727.
18. Kourembanas S, Maraden PA, McQuillan LP, et al. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88:1054-1057.
19. Bodi I, Bishopric NM, Discher DJ, et al. Cell specificity and signalling pathway of endothelin-1 gene regulation by hypoxia. Cardiovasc Res 1995;30:975-980.
20. Pedram A, Rasandi M, Hu RM, et al. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997;272:17097-17103.
21. Salani D, Taraboletti LR, di Castro V, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-1711.
22. Ripodas A, de Juan JA, Roldán-Pallarés, et al. Localisation of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eyes. Evidence for endothelin-1 expression in astrocytes. Brain Res 2001;912:137-143.
23. De Juan JA, Moya JF, Ripodas A, et al. Changes in the density and localization of endothelin receptors in the early stages of rat diabetic retinopathy and the effect of insulin treatment. Diabetologia 2000;43:773-785.
24. Klein R. Diabetic retinopathy. Annu Rev Public Health 1996;17:137-158.
25. Fong DS, Ferris FL III, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999;127:137-141.
26. Frank RN, Amin RH, Eliot D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403.
27. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factor I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest 1993;92:2620-2625.
28. De Juan JA, Moya FJ, Fernández- Cruz A, et al. Identification of receptor subtypes in rat retina using subtype-selective ligands. Brain Res 1995;690:25-33.
29. Lowry OH, Rosebrough NH, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
30. Roldán-Pallarés M, Rollín R, Mediero A, et al. Immunoreactive ET-1 in the vitreous humour and epiretinal membranes of patients with proliferative vitreoretinopathy. Mol Vis 2005;11:461-471.
31. Fernandez-Durango R, Rollin R, Mediero A, et al. Localization of endothelin-1 mRNA expression and immunoreactivity in the anterior segment of human eye: expression of ETA and ETB receptors. Mol Vis 2003;9:103-109.
32. Cunha-Vaz JG. Studies on the pathophysiology of diabetic retinopathy. The blood-retinal barrier in diabetes. Diabetes 1983;32:20-27.
33. Pournaras CJ. Retinal oxygen distribution: its role in the physiopathology of vasoproliferative microangiopathies. Retina 1995;15:332-347.
34. Narayan S, Prasanna G, Krishnamoorthy RR, et al. Endothelin-1 synthesis and secretion in human retinal pigment epithelial cells (ARPE- 19). Differential regulation by cholinergics and TNF-α. Invest Ophthalmol Vis Sci 2003;44:4885-4894.
35. Ogata M, Naruse M, Iwasaki N, et al. Immunoreactive endothelin levels in the vitreous fluid are decreased in diabetic patients with proliferative retinopathy. J Cardiovasc Pharmacol 1998;31:S378- S379.
36. Oku H, Kida T, Sugiyama T, et al. Possible involvement of endothelin-1 and nitric oxide in the pathogenesis of proliferative diabetic retinopathy. Retina 2001;21:647-651.
37. Fernández- Cruz A, Patiño R, Ibarra J, et al. Endothelin in hypertension and diabetes mellitus. In: Lüscher TF, ed. The Endothelium in Cardiovascular Disease. New York: Springer-Verlag; 1995:157-170.
38. Kawamura M, Ogawara H, Naruse M, et al. Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 1992;15:1396-1397.
39. Laurenti O, Vignolo EM, Desideri GB, et al. Increased levels of plasma endothelin-1 in insulin dependent diabetic patients with retinopathy but without other diabetes related organ damage. Exp Clin Endocrinol Diabetes 1997;105:S40-42.
40. Wiedemann P. Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy and retinal degeneration. Surv Ophthalmol 1992;36:373-384.
41. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors and synthetic chemoattractant. Am J Ophthalmol 1978;86:455-461.
42. Campochiaro PA, Brian JA III, Conway BP, Jaccoma ET. Intravitreal chemotactic and mitogenic activity: implication of blood-retinal barrier breakdown. Arch Ophthalmol 1986;104:1685-1687.
43. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol 1984;102:1830-1833.
44. Leschey KH, Hackett SF, Singer JH, Campochiaro PA. Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1990;31:839-846.
45. McCumber MW, D'Anna SA. Endothelin receptor- binding subtypes in the human retina and choroids. Arch Ophthalmol 1994;112:1231-1235.
46. Park JK, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose. An effect of protein kinase C activation. Diabetes 2000;49:1239-1248.
47. Takagi C, Bursell SF, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996;37:2504-2518.
48. Aiello LP, Pierce FA, Foley FD, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
49. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophthalmol 1996;114:66-71.
50. Seo MS, Kwak N, Ozaki K, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol 1999;154:1743-1753.
51. Aiello LP, Bursell SF, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
52. 2 release. Am J Hypertens 1997;10:32-42.